ERBB2 and breast carcinoma: Since an initial evaluation suggested that [99mTc]Tc-ADAPT6 provides a higher uptake (SUVmax) in HER2-positive breast cancer lesions than 99mTc-labeled DARPin G3 [23], [99mTc]Tc-ADAPT6 was selected for further clinical evaluation.